A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael N Needle, MD
AVEO Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
- North Coast Cancer Institute
Coffs Harbour, New South Wales, Australia
- Concord Repatriation General Hospital
Concord, New South Wales, Australia
- Townsville Hospital
Douglas, Queensland, Australia
- Icon Cancer Care
Southport, Queensland, Australia
- Princess Alexandra Hospital
Wolloongabba, Queensland, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Eastern Health
Box Hill, Victoria, Australia
- Frankston Hospital
Frankston, Victoria, Australia
- Ballarat Oncology and Haematology
Wendouree, Victoria, Australia
- Tuen Mun Hospital
Tuenmen, N.T, Hong Kong
- Queen Mary Hospital
Pok Fu Lam, Hong Kong
- Ao G.Rummo
Benevento, Italy
- Policlinico S.Orsola Malpighi
Bologna, Italy
- Istituti Ospitalieri Di Cremona - Oncologia
Cremona, Italy
- U.O.C. Oncologia
Lucca, Italy
- Irccs Ospedale S.Raffaele
Milan, Italy
- Fondazione Salvatore Maugeri
Pavia, Italy
- Irccs Istituto Clinico Humanitas
Rozzano MI, Italy
- Ospedale Treviglio-Caravaggio
Treviglio BG, Italy
- John Hopkins Singapore International Medical Center
Central Singapore, Singapore
- National Cancer Centre
Singapore, Singapore
- Korea University Guro Hospital
Guro-gu, Seoul, South Korea
- Chungbuk National University Hospital
Chungcheongbuk-do, South Korea
- Chonnam National University Hwasun Hospital
Jeonnam, South Korea
- Samsung Medical Center
Seoul, South Korea
- Severance Hospital, Yonsei Uni
Seoul, South Korea
- China Medical University Hospital
Taichung, Taiwan
- Chung Shan Medical University
Taichung, Taiwan
- National Cheng Kung University
Tainan, Taiwan
- National Taiwan University Hospital
Taipei, Taiwan
- Taipei Medical University
Taipei, Taiwan
- Taipei Veterans General Hospital
Taipei, Taiwan
- Chang Gung Medical Foundation
Taoyuan City, Taiwan
- Ucsf Fresno
Fresno, California, United States
- Torrance Memorial Medical Center
Redondo Beach, California, United States
- Boca Raton Regional Hospital Lynn Cancer Institute
Boca Raton, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach
Deerfield Beach, Florida, United States
- Kaiser Permanente Hawaii
Honolulu, Hawaii, United States
- Cancer Center of Acadiana
Lafayette, Louisiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2014
- Primary completion
- 31 Jan 2017
- Completion
- 31 Jan 2017
- Last update posted
- 22 Oct 2020
- Registered enrollment
- 10
- Registry id
- NCT02318368
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.